February 16, 2015
Wellesley, Mass., February 16, 2015 –BCC Research (www.bccresearch.com) reveals in its new report on fetal monitoring, diagnostics and predictive tests, that since the last decade there has been an increase of high-risk pregnancies that has necessitated the applications of high level fetal and maternal monitoring during pregnancies around the globe. With such growing demand for fetal monitoring technologies, healthcare vendors are constantly developing and offering new technologies to meet the challenges posed by complicated pregnancies.
Pregnancies become complicated due to change in lifestyle of women, conception after age 35 or when the women are just in their teens, obesity and diabetes in the child-bearing age and the success of assisted-reproduction. As nearly as 80% of live births are associated with a pregnancy-related complication, and in most delivery care settings, fetal monitoring has become a standard of care.
Fetal monitoring is usually performed with an electronic fetal heart rate monitor (FHR) or a hand-held Doppler device or a fetoscope. Electronic fetal monitors is estimated to grow from nearly $531.3 million in 2013 to $657.1 million in 2019. Fetoscopes, fetal scalp electrodes and intrauterine pressure catheters achieved a market share of $76.2 million in 2013 and have the potential to earn $103.4 million in 2019.
Effective and timely utilization of fetal monitoring and diagnostic testing procedures bring about significant improvements in perinatal outcome. “Today, fetal medicine is a quickly growing field of expansive dimensions. The ever increasing development in fetal monitoring devices, prenatal diagnostic tests and neonatal surveillance technologies are enabling fetal medicine experts to foresee all the preventable fetal disorders beforehand,” says BCC Research analyst P. Natana Raj.
Fetal Monitoring, Diagnostics and Predictive Tests provides the current and projected markets for FHS monitors, fetal Dopplers, fetoscopes, fetal ultrasound systems, invasive prenatal diagnostics, noninvasive prenatal diagnostics, predictive diagnostics, preimplantation genetic diagnostics (PGD) and preimplantation genetic screening (PGS) tests.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
Fetal Monitoring, Diagnostics and Predictive Tests( HLC089B )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.